Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma

Gene Therapy

Volumn 10, Issue 14, 2003, Pages 1198-1204

  Barker, S D ^a,b,c   Dmitriev, I P ^a,b   Nettelbeck, D M ^a,b   Liu, B ^a,b   Rivera, A A ^a,b   Alvarez, R D ^b,c   Curiel, D T ^a,b,c   Hemminki, A ^a,b,c,d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Adenovirus; C erbB 2; Ovarian carcinoma; Secretory leukoprotease inhibitor; Tissue specific promoters; Transcriptional targeting; Transductional targeting

Indexed keywords

ADAPTOR PROTEIN; ADENOVIRUS VECTOR; GROWTH FACTOR RECEPTOR; RECEPTOR PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL KILLING; CONTROLLED STUDY; COXSACKIE VIRUS; CYTOMEGALOVIRUS; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER; ONCOGENE NEU; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; TISSUE SPECIFICITY; TRANSGENE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; ANTIBODIES; CYTOMEGALOVIRUS; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; LIVER; LUCIFERASES; MICE; MICE, SCID; MODELS, ANIMAL; OVARIAN NEOPLASMS; PROMOTER REGIONS (GENETICS); PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; RECEPTOR, ERBB-2; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; TRANSCRIPTION, GENETIC; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; COXSACKIEVIRUS; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; FALLOPIA;

EID: 0041308272     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301974     Document Type: Article

References (18)

1. Tomko RP, Xu R, Philipson L. The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsakieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
2. Yang Y. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
3. Yang Y. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
4. Bauerschmitz G, Barker S, Hemminki A. Adenoviral gene therapy for cancer - from vectors to targeted and replication competent agents. Int J Oncol 2002; 21(6): 1164-1174.
5. Curiel D. Strategies to adapt adenoviral vectors for targeted delivery. Ann NY Acad Sci 1999; 886: 158-171.
6. Kashentseva E et al. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res 2001; 62: 609-616.
7. Agus D et al. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000; 27: 53-63.
8. Hung M, Lau Y. Basic science of HER-2/neu: a review. Semin Oncol 1999; 26: 51-59.
9. Nettelbeck D, Jerome V, Muller R. Gene therapy: designer promoters for tumour targeting. Trends Genet 2000; 16: 174-181.
10. Barker S et al. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med 2002; (in press).
11. Kanerva A et al. Gene transfer to ovarian cancer versus normal tissues with fiber modified adenoviruses. Mol Ther 2002; 5: 695-704.
12. Reynolds P et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotech 2001; 19: 838-842.
13. Robertson M et al. Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells. Cancer Gene Ther 1998; 5: 331-336.
14. Barker S et al. (2002). The regulatory sequences of the secretory leukoprotease inhibitor gene as a promising tissue-specific promoter for ovarian cancer gene therapy. In: American Society of Gene Therapy. Boston, MA.
15. Barker S et al. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol 2001; 82: 57-63.
16. Raper S et al. A pilot study on in vivo-directed gene transfer with an adenoviral vector in partial orthinine transcarbamylase defiency. Hum Gene Ther 2002; 13: 163-175.
17. Casado E et al. Transcriptional targeting for ovarian cancer gene therapy. Gynecol Oncol 2001; 82: 229-237.
18. Qiao J et al. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Therapy 2002; 9: 168-175.